This web site is part of the Business Intelligence Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
Alethia BioTherapeutics Inc.
Drug Names(s): AB-16B5
Description: AB-16B5 is a monoclonal antibody that inhibits metastasis invasion and enhances response to chemotherapy by inhibiting epithelial-to-mesenchymal transition (EMT) and stem cell markers. It targets clusterin (sCLU), a secreted protein which promotes EMT, a key process in metastatic invasion.
Alethia and IBC Generium
In May 2013, Alethia Biotherapeutics entered into a global strategic alliance with the IBC Generium to jointly develop AB-16B5.
Under the terms of the alliance, Alethia and IBC Generium will collaborate for the ongoing development of AB-16B5 and, upon completion of the initial clinical study, share equally in the downstream economics in territories outside Russia and the CIS states. Alethia will receive an upfront cash payment and R&D funding to conduct the initial clinical study in Canada. In addition to an exclusive license granted to IBC Generium for other territories, IBC Generium has also been granted the right to an exclusive license for Russia and the CIS states for which development milestones and royalties would be payable to Alethia. Further financial terms were not disclosed.
Partners: International Biotechnology Center (IBC) Generium
Additional information available to subscribers only: